IP Library Granted Patent US 10,793,907
Granted Patent B2
US 10,793,907 · App. 15/207,930 · Granted Oct 6, 2020

Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions

Inventors: Zachary Apte (San Francisco, CA); Daniel Almonacid (San Francisco, CA); Jessica Richman (San Francisco, CA); Siavosh Rezvan Behbahani (San Francisco, CA)
Assignee: PSOMAGEN, INC.
C12Q1/6883A61K35/741C12Q1/689G16B10/00G16B20/00G16B50/00C12Q2600/112G16H50/50Y02A90/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,907
App. No.
15/207,930
Granted
Oct 6, 2020
Kind
B2
Abstract

A method for at least one of characterizing, diagnosing, and treating an endocrine system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the endocrine system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the endocrine system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

Claims (36)

1. A method for diagnosing and treating Graves' disease, the method comprising:

at a sample handling network, processing content of a sample from a subject, thereby generating a microbiome composition dataset and a microbiome functional diversity dataset associated with the sample;

at a computing system in communication with the sample handling network, identifying an association between the sample and at least one of a taxonomic feature from the microbiome composition dataset and a functional feature from the microbiome functional diversity dataset;

based upon the association, diagnosing the subject with Graves' disease; and

providing a therapy to the subject, wherein providing the therapy comprises promoting a microbiome modifying therapy to the subject in order to improve a health state of the subject with Graves' disease.

2. The method of claim 1 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and a first taxonomic feature related to Aerococcaceae (family).

3. The method of claim 2 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of: a second taxonomic feature related to Peptostreptococcus (genus) and a third taxonomic feature related to Fastidiosipila (family).

4. The method of claim 3 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and a fourth taxonomic feature related to Methanobrevibacter (genus).

5. The method of claim 4 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of: a fifth taxonomic feature related to Facklamia (genus), a sixth taxonomic feature related to Methanobacteriaceae (family), and a seventh taxonomic feature related to Euryarchaeota (phylum).

6. The method of claim 1 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a set of functional features, wherein the set of functional features derived from one or more of: clusters of orthologous groups of proteins features, genomic functional features, gene ontology features, chemical functional features, and systemic functional features.

7. The method of claim 6 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a first functional feature related to “D-alanine metabolism”.

8. The method of claim 7 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a second functional feature related to “Nucleotide metabolism”.

9. The method of claim 8 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a third functional feature related to “Translation proteins”.

10. The method of claim 9 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a fourth functional feature related to “Replication and repair”.

11. The method of claim 9 , wherein diagnosing the subject with Graves' disease comprises identifying an association between the sample and at least one of a fifth functional feature related to “DNA repair and recombination proteins”.

12. The method of claim 9 , wherein diagnosing the subject with Grave's disease comprises identifying an association between the sample and at least one of a sixth functional feature related to “Peptidases”.

13. The method of claim 1 , wherein providing the therapy comprises promoting at least one of a probiotic therapy and a prebiotic therapy to the subject, wherein the therapy comprises a consumable that modify at least one of: i) affects a microorganism component of the subject and 2) selectively modulates a population size of at least one desired taxon associated with improving the health state of the subject with Graves' disease.

14. A method for characterizing Graves' disease, the method comprising:

at a sample handling network, receiving an aggregate set of samples from a population of subjects;

at a computing system in communication with the sample handling network, generating at least one of a microbiome composition dataset and a microbiome functional feature dataset for the population of subjects upon processing content of each of the aggregate set of samples;

at the computing system, receiving a supplementary dataset that is informative of Graves' disease presence within the population of subjects;

at the computing system, transforming the supplementary dataset and features extracted from at least one of the microbiome composition and the microbiome functional feature datasets into a characterization model of Graves' disease; and

based upon the characterization model, generating a therapy model; and

providing a therapy to the subject, in accordance with the therapy model, wherein providing the therapy comprises promoting the therapy configured to improve a health state of an individual diagnosed with Graves' disease by the characterization model.

15. The method of claim 14 , wherein processing content of each of the aggregate set of samples comprises at least one of: processing nucleic content with a fragmentation operation, a multiplexed amplification operation using a set of primers, and a sequencing analysis operation.

16. The method of claim 14 , further comprising: diagnosing the individual with Graves' disease, upon generating an association between a sample processed from the individual and a set of taxonomic features and a set of functional features according to the characterization model.

17. The method of claim 16 , wherein the set of taxonomic features includes at least one of: a first taxonomic feature associated with Aerococcaceae (family) and a second taxonomic feature associated with Peptostreptococcus (genus), and wherein the set of functional features includes at least one of: a first functional feature related to D-Alanine metabolism and a second functional feature related to translation proteins.

18. The method of claim 16 , wherein the set of taxonomic features further includes at least one of: a third taxonomic feature associated with Fastidiosipila (family) and a fourth taxonomic feature associated with Methanobrevibacter (genus), and wherein the set of functional features further includes at least one of: a third functional feature related to nucleotide metabolism and a fourth functional feature related to replication and repair.

19. The method of claim 18 , further comprising: at an output device associated with the individual and in communication with the computing system, promoting a therapy to the individual diagnosed with Graves' disease, in accordance with the therapy model, wherein promoting the therapy comprises promoting a microbiome-modifying therapy to the individual, the microbiome modifying therapy comprising a consumable configured to affect a taxonomic group associated with at least one of the set of taxonomic features and the set of functional features, in order to improve a health state the individual with Graves' disease.

20. A method for diagnosing and treating Graves' disease, the method comprising:

at a sample handling network, processing nucleic acid content of a sample from a subject, thereby generating a microbiome composition dataset associated with the sample;

at a computing system in communication with the sample handling network, identifying an association between the sample and a taxonomic feature from the microbiome composition dataset wherein the taxonomic feature is associated with at least one of Aerococcaceae (family) and Peptostreptococcus (genus);

based upon the association, diagnosing the subject with Graves' disease; and

providing a therapy to the subject, wherein providing the therapy comprises promoting a microbiome modifying therapy to the subject in order to improve a health state of the subject with Graves' disease.

21. The method of claim 20 , wherein identifying the association further includes identifying the association between the sample and: a third taxonomic feature related to Fastidiosipila (genus) and a first functional feature related to D-Alanine metabolism.

22. The method of claim 21 , wherein identifying the association further includes identifying the association between the sample and: a fourth taxonomic feature related to Methanobrevibacter (genus) and a second functional feature related to translation proteins.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: UBIOME, INC.
To: PSOMAGEN, INC.
Reel/Frame 051586/0274 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: ALMONACID, DANIEL; APTE, ZACHARY; RICHMAN, JESSICA; BEHBAHANI, SIAVOSH REZVAN
To: UBIOME, INC.
Reel/Frame 039264/0190 →
Continuity (20)
Continuation 15098248 · Apr 13, 2016
Continuation In Part 14919614 · Oct 21, 2015
Continuation In Part 15207930
Continuation 15098248 · Apr 13, 2016
Provisional Application 62066369 · Oct 21, 2014
Provisional Application 62087551 · Dec 4, 2014
Provisional Application 62092999 · Dec 17, 2014
Provisional Application 62147376 · Apr 14, 2015
Provisional Application 62147212 · Apr 14, 2015
Provisional Application 62147362 · Apr 14, 2015
Provisional Application 62146855 · Apr 13, 2015
Provisional Application 62206654 · Aug 18, 2015
Provisional Application 62147058 · Apr 14, 2015
Provisional Application 62147107 · Apr 14, 2015
Provisional Application 62147202 · Apr 14, 2015
Provisional Application 62147226 · Apr 14, 2015
Provisional Application 62147304 · Apr 14, 2015
Provisional Application 62147348 · Apr 14, 2015
Provisional Application 62147355 · Apr 14, 2015
Related Publication 20160319358A1 · Nov 3, 2016